Effects of danshensu on maternal syndrome in phosphatidyleserine/ phosphatidylcholine microvesicle induced-mouse model: Is it a candidate for preeclampsia remedy?

Chinese Medical Journal

Volumn 123, Issue 7, 2010, Pages 895-900

  Shen, Yang ^a   Hu, Ya Li ^b   Zhang, Yan ^b   Wang, Jing Mei ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Anticoagulants; Danshensu; Hemostasis; Mice; Preeclampsia

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; ANTITHROMBIN III; D DIMER; HEPARIN; LYSINE ACETYLSALICYLATE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; THROMBOMODULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FIBRIN DEPOSITION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NONHUMAN; PREECLAMPSIA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; THROMBIN TIME; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; ASPIRIN; DISEASE MODELS, ANIMAL; FEMALE; HEPARIN; LACTATES; MICE; MICE, INBRED ICR; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLSERINES; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RANDOM ALLOCATION; THROMBOMODULIN;

EID: 77950912327     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.07.024     Document Type: Article

References (27)

1. Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol 2009; 33: 196-205.
2. Brenner B, Aharon A. Thrombophilia and adverse pregnancy outcome. Clin Perinatol 2007; 34: 527-541, v.
3. Roberts DJ, Post MD. The placenta in pre-eclampsia and intrauterine growth restriction. J Clin Pathol 2008; 61:1254-1260.
4. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294:H541-H550.
5. Omatsu K, Kobayashi T, Murakami Y, Suzuki M, Ohashi R, Sugimura M, et al. Phosphatidylserine/phosphatidylcholine microvesicles can induce preeclampsia-like changes in pregnant mice. Semin Thromb Hemost 2005; 31: 314-320.
6. Saisto T, Tiitinen A, Ulander VM, Kaaja R. Clinical cure of severe, early onset preeclampsia with low molecular weight heparin therapy in primigravida with hyperreactio luteinalis and thrombophilia. Hum Reprod 2004; 19: 725-728.
7. Vormittag R, Pabinger I. Thrombophilia and pregnancy complications. Hamostaseologie 2006; 26: 59-62.
8. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-1798.
9. Ruano R, Fontes RS, Zugaib M. Prevention of preeclampsia with low-dose aspirin-a systematic review and meta-analysis of the main randomized controlled trials. Clinics 2005; 60: 407-414.
10. McCoy S, Baldwin K. Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm 2009; 66: 337-344.
11. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005; 45: 1345-1359.
12. Chen LN, Zhu XX. Advances in study of the pharmacological effects of danshen on hemorheology. Chin J Chin Materia Med (Chin) 2005; 30: 630-633,640.
13. Zhang Y, Hua Z, Zhang K, Meng K, Hu Y. Therapeutic effects of anticoagulant agents on preeclampsia in a murine model induced by phosphatidylserine/phosphatidylcholine microvesicles. Placenta 2009; 30: 1065-1070.
14. Ogawa H, Yonezawa S, Maruyama I, Matsushita Y, Tezuka Y, Toyoyama H, et al. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett 2000; 149: 95-103.
15. VanWijk MJ, Boer K, Berckmans RJ, Meijers JC, van der Post JA, Sturk A, et al. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002; 88: 415-420.
16. Chan WS, Chunilal SD, Ginsberg AS. Antithrombotic therapy during pregnancy. Semin Perinatol 2001; 25: 165-169.
17. Knight M, Duley L, Henderson-Smart DJ, King JF. WITHDRAWN: Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2007; 18: CD000492.
18. Le Templier G, Rodger MA. Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 2008; 14: 403-407.
19. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112: 2607-2616.
20. Chandiramani M, Seed P, Poston L, Shennan AH. Antiplatelet agents for prevention of pre-eclampsia. Lancet 2007; 370:1685.
21. Roberts JM, Catov JM. Aspirin for pre-eclampsia: compelling data on benefit and risk. Lancet 2007; 369: 1765-1766.
22. Lam FF, Yeung JH, Chan KM, Or PM. Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels. Vascul Pharmacol 2007; 46: 271-277.
23. Zhao GR, Zhang HM, Ye TX, Xiang ZJ, Yuan YJ, Guo ZX, et al. Characterization of the radical scavenging and antioxidant activities of danshensu and salvianolic acid B. Food Chem Toxicol 2008; 46: 73-81.
24. Chan K, Chui SH, Wong DY, Ha WY, Chan CL, Wong RN. Protective effects of danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci 2004; 75: 3157-3171.
25. Ding M, Yuan YJ. Study on the mechanisms of an extract of Salvia miltiorrhiza on the regulation of permeability of endothelial cells exposed to tumour necrosis factor-α. J Pharm Pharmacol 2007; 59: 1027-1033.
26. Wang RG, You ZL, Liu XL. Effect of ingredients of Astragalus-Salvia compound on vascular endothelial cell in placenta and vascular endothelial growth factor mRNA expression in trophocyte in pregnant rats with inhibited nitric oxide synthesis. Chin J Integr Tradit West Med (Chin) 2005; 25: 516-519.
27. Gao Y, Liu Z, Li G, Li C, Li M, Li B. Acute and subchronic toxicity of danshensu in mice and rats. Toxicol Mech Methods 2009; 19: 363-368.